Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Phase II Study on Axitinib in Advanced Solitary Fibrous Tumor

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02261207
Recruitment Status : Unknown
Verified October 2014 by Fondazione IRCCS Istituto Nazionale dei Tumori, Milano.
Recruitment status was:  Not yet recruiting
First Posted : October 10, 2014
Last Update Posted : October 10, 2014
Sponsor:
Information provided by (Responsible Party):
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Brief Summary:
This is an investigator initiated, open label, prospective, non-randomized, phase II trial aimed at evaluating the activity of Axitinib in progressive VEGFR2 and/or PDGFRB positive advanced Solitary Fibrous Tumor (SFT) patients. Patients with a documented and centrally reviewed pathologic and radiologic diagnosis of progressive VEGFR2 and/or PDGFRB positive advanced SFT may enter in the study. Axitinib will be administered at the dose of 5mg twice a day, continuously. Treatment will be continued till evidence of progression, or toxicities or patient withdrawal.

Condition or disease Intervention/treatment Phase
Solitary Fibrous Tumor Drug: Axitinib Phase 2

Detailed Description:

This is an investigator initiated, open label, prospective, non-randomized, phase II trial aimed at evaluating the activity of Axitinib in progressive VEGFR2 and/or PDGFRB positive advanced Solitary Fibrous Tumor (SFT) patients. Patients with a documented and centrally reviewed pathologic and radiologic diagnosis of progressive VEGFR2 and/or PDGFRB positive advanced SFT may enter in the study. Axitinib will be administered at the dose of 5mg twice a day, continuously. Treatment will be continued till evidence of progression, or toxicities or patient withdrawal.

The activity of Axitinib will be evaluated in terms of overall response rate according to Choi Criteria as defined for GIST patients treated with Imatinib, extended even to MRI.

Secondary objectives of the study will be: response rate by RECIST, progression free survival, overall survival, clinical benefit (RECIST Complete Response + Partial Response + Stable Disease >6 months). Whenever possible a post-treatment biopsy will be performed to assess Axitinib targets status after treatment and to correlate their status to the response.

Tumor assessment with CT scan and/or MRI will be performed within 4 weeks prior to first dose of Axitinib and after 4 weeks from starting treatment, then every 2 months until progression or toxicity.

As per protocol the experimental treatment can be administered in front or further line.

The study will be considered positive if 30% of response rate by Choi criteria is observed. To this end a maximum of 16 evaluable patients will be enrolled in two years.

In case of positive study the trial will be re-open to confirm the result in a larger number of patients.

.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 16 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study on Axitinib in Advanced VEGFR and/or PDGFR Solitary Fibrous Tumor
Study Start Date : November 2014
Estimated Primary Completion Date : March 2018
Estimated Study Completion Date : March 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Axitinib

Arm Intervention/treatment
Experimental: Axitinib
Axitinib will be administered at the dose of 5mg twice a day, continuously. Treatment will be continued till evidence of progression, or toxicities or patient withdrawal.
Drug: Axitinib
Axitinib will be administered at the dose of 5mg twice a day, continuously. Treatment will be continued till evidence of progression, or toxicities or patient withdrawal.
Other Name: Inlyta




Primary Outcome Measures :
  1. Response rate by Choi criteria [ Time Frame: 4 years ]
    response rate, according to Choi Criteria


Secondary Outcome Measures :
  1. Response rate by RECIST criteria [ Time Frame: 4 years ]
    response rate according to RECIST


Other Outcome Measures:
  1. Overall survival [ Time Frame: 4 years ]
    Evaluation of overall survival

  2. Progression Free Survival [ Time Frame: 4 years ]
    Evaluation of Progression Free Survival

  3. Clinical Benefit [ Time Frame: 4 years ]
    Evaluation of clinical benefit according to response rate, overall survival, progression free survival

  4. Post-treatment Axitinib target status assessment [ Time Frame: 4 years ]
  5. Safety essessment [ Time Frame: 4 years ]
    assessment of the safety profile of Axitinib in agreement with the incidence of related adverse events.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pat centrally confirmed diagnosis of solitary fibrous tumor
  • Expression of PDGFRB and/or VEGFR2 by immunohistochemistry on formalin fixed-paraffin embedded (FFPE) material as minimal requirement. Activation of PDGFRB and/or VEGFR2 by real time C reactive protein of PDGFB and VEGFA on FFPE material (if in sufficient quantity) or by biochemistry on frozen material (if available)
  • Locally advanced disease (i.e. surgical resection of local disease unfeasible radically, or unaccepted by the patient, or amenable to become less demolitive, or feasible, or easier, after cytoreduction) and/or metastatic disease
  • Measurable disease
  • Centrally confirmed evidence of progression by RECIST during the 6 months before study entry
  • 1st-line vs 3-rd-line
  • Eastern Cooperative Oncology Group (ECOG) Performance Status = 0, 1, 2
  • Adequate bone marrow function, defined as the following: absolute neutrophil count (ANC) >1.5 x 109/L, platelets >100 x 109/L, Hb >9 g/dL. Blood transfusions are allowed to reach the baseline requested Hb level
  • Adequate organ function, defined as the following: total bilirubin within normal institutional limits (but in case of Gilbert's syndrome), aspartate aminotransferase (AST) and Serum Glutamic Pyruvic Transaminase (ALT) <2.5 x upper normal limit (UNL), creatinine <1.5 x upper normal limit (UNL), within normal institutional limits or creatinine clearance ≥60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
  • Cardiac ejection fraction ≥50% as measured by echocardiogram
  • Age > 18 yrs
  • Female patients of child-bearing potential must have negative pregnancy test within 7 days before initiation of study drug dosing. Post-menopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential. Male and female patients of reproductive potential must agree to employ an effective method of birth control throughout the study and for up to 3 months following discontinuation of study drug
  • No history of arterial and/or venous thromboembolic event within the previous 12 months
  • Written, voluntary informed consent

Exclusion Criteria:

  • Other primary malignancy with <5 years clinically assessed disease-free interval, except basal cell skin cancer, cervical carcinoma in situ, or other neoplasms judged to entail a low risk of relapse
  • Previous treatment with any other investigational or not investigational agents and or radiation therapy within 28 days of first day of study drug dosing, or patients who have not recovered from adverse events due to agents administered more than 4 weeks earlier
  • Major surgery within 2 weeks prior to study entry
  • Previous radiotherapy to ≥25 % of the bone marrow
  • Concomitant other investigational agents or concurrent anticancer therapy. In addition, all herbal (alternative) medicines are excluded
  • Grade III/IV cardiac problems as defined by the New York Heart Association Criteria (i.e., history of uncontrolled or symptomatic angina, history of arrhythmias requiring medications, or clinically significant, with the exception of asymptomatic atrial fibrillation requiring anticoagulation, myocardial infarction < 6 months from study entry, uncontrolled or symptomatic congestive heart failure, ejection fraction below the institutional normal limit)
  • Known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment)
  • Known diagnosis of human immunodeficiency virus (HIV) infection
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to Axitinib
  • Expected non-compliance to medical regimens

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02261207


Contacts
Layout table for location contacts
Contact: Silvia Stacchiotti, MD +39 022390 ext 2807 silvia.stacchiotti@istitutotumori.mi.it

Locations
Layout table for location information
Italy
Fondazione IRCCS Istituto Naazionale dei Tumori Not yet recruiting
Milan, MI, Italy, 20133
Contact: Silvia Stacchiotti, MD    +39 022390 ext 2807    silvia.stacchiotti@istitutotumori.mi.it   
Principal Investigator: Silvia Stacchiotti, MD         
Sponsors and Collaborators
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Investigators
Layout table for investigator information
Principal Investigator: Silvia Stacchiotti, MD Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Layout table for additonal information
Responsible Party: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
ClinicalTrials.gov Identifier: NCT02261207     History of Changes
Other Study ID Numbers: SFT-AX2014
2013-005596-40 ( EudraCT Number )
First Posted: October 10, 2014    Key Record Dates
Last Update Posted: October 10, 2014
Last Verified: October 2014

Additional relevant MeSH terms:
Layout table for MeSH terms
Solitary Fibrous Tumors
Neoplasms, Fibrous Tissue
Neoplasms, Connective Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms
Axitinib
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action